Revvity, Inc.
Revvity, Inc. (RVTY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
rvty · pe ratio · data through Dec 28, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Revvity, Inc. (RVTY) measures how much investors pay for each dollar of the company's trailing earnings. RVTY's current PE ratio of 46.57x is calculated by dividing its stock price of $100.30 by its TTM earnings per share of $2.15. +37.4% elevated vs 5Y avg 33.9x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-28
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 19 fiscal years · Front-end computedMinQ1 · 25%28.4x
MedianQ3 · 75%1927.9x
Max
At 46.57x, RVTY's current P/E is higher than in 79% of its annual fiscal year readings over the past 19 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Diagnostics & Research · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Revvity, Inc.You RVTY | $11.2B | 46.57x | +23.1% | $2.15 |
 Align Technology, Inc. ALGN | $12.3B | 27.60x | -27.1% | $5.66 |
 Charles River Laboratories International, Inc. CRL | $9.0B | N/A | — | -$2.91 |
 The Ensign Group, Inc. ENSG | $9.1B | 29.02x | -23.3% | $6.00 |
 Exact Sciences Corporation EXAS | $20.0B | N/A | — | -$1.10 |
 Guardant Health, Inc. GH | $16.6B | N/A | — | -$3.32 |
 Hims & Hers Health, Inc. HIMS | $6.1B | 56.90x | +50.4% | $0.57 |
Industry Average 3 peers with valid PE | — | 37.84x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-28Latest FY2025 | 45.49x | $2.13 | -1.5% | |
2024-12-29 FY2024 | 46.19x | $2.41 | — | |
2023-12-31 FY2023 | — | $-0.95 | — | |
2022-12-31 FY2022 | 31.08x | $4.51 | +25.5% | |
2021-12-31 FY2021 | 24.76x | $8.12 | +12.7% | |
2020-12-31 FY2020 | 21.98x | $6.53 | -53.5% | |
2019-12-31 FY2019 | 47.29x | $2.05 | +30.0% | |
2018-12-31 FY2018 | 36.37x | $2.16 | -49.4% | |
2017-12-31 FY2017 | 71.84x | $1.03 | +194.1% | |
2016-12-31 FY2016 | 24.43x | $2.13 | -13.9% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Revvity, Inc. (RVTY) measures how much investors pay for each dollar of the company's trailing earnings. RVTY's current PE ratio of 46.57x is calculated by dividing its stock price of $100.30 by its TTM earnings per share of $2.15.
Frequently asked questions
RVTY pe ratio · 6 questionsRVTY's current PE ratio is 46.57x as of 2026-06-08, based on a stock price of $100.30 and TTM EPS of $2.15. Data sourced from Financial Modeling Prep via RVTY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Revvity, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08